23 April 2026 - Debiopharm today announced that the US FDA has granted fast track designation to the combination of its ...
22 April 2026 - Labcorp today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion ...
22 April 2026 - Approval is based on pivotal Phase 2 FIREFLY-1 data demonstrating meaningful and durable tumour responses. ...
21 April 2026 - A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended ...
20 April 2026 - BridgeBio Oncology Therapeutics today announced that the US FDA has granted fast track designation to BBO-11818 for ...
20 April 2026 - Astellas Pharma and Pfizer announced that the US FDA accepted for triority review a supplemental biologics license ...
17 April 2026 - NICE has recommended a new take at home tablet for some people with chronic lymphocytic leukaemia whose ...
16 April 2026 - The Australian Government is continuing to deliver cheaper medicines with Australians living with lung or bladder ...
15 April 2026 - Opna Bio today announced that the US FDA has granted fast track designation to OPN-6602, a dual ...
14 April 2026 - Partner Therapeutics announces the submission of a supplemental biologics license application to the US FDA for Bizengri ...
14 April 2026 - Renaissance Pharma Limited, an Essential Pharma company, today announces that the US FDA has granted fast track ...
14 April 2026 - Pharmaceutical giant Pfizer has abandoned negotiations to have a breakthrough cancer drug listed on the Pharmaceutical ...
9 April 2026 - Celltrion announced Thursday that the US FDA has granted fast track designation to its antibody-drug conjugate ...
9 April 2026 - From 1 May 2026, people living with chronic lymphocytic leukaemia will be able to access two ...
7 April 2026 - April Cancer Awareness Month a good time for concrete action ...